
Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements Guidance for Industry

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <https://www.regulations.gov>. Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document, contact (CDER) Elizabeth Pepinsky, 301-796-1200; (CBER) Office of Communication, Outreach and Development, 800-835-4709 or 240-402-8010; or (CVM) Thomas Moskal, 240-402-6251.

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
Center for Veterinary Medicine (CVM)**

**October 2018
Advertising**

Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements Guidance for Industry

Additional copies are available from:

*Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10001 New Hampshire Ave., Hillandale Bldg., 4th Floor
Silver Spring, MD 20993-0002
Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353
Email: druginfo@fda.hhs.gov*

*<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>
and/or*

*Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 71, Room 3128
Silver Spring, MD 20993-0002
Phone: 800-835-4709 or 240-402-8010
Email: ocod@fda.hhs.gov*

*<http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>
and/or*

*Policy and Regulations Staff, HFV-6
Center for Veterinary Medicine
Food and Drug Administration
7519 Standish Place, Rockville, MD 20855*

<http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/default.htm>

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
Center for Veterinary Medicine (CVM)**

**October 2018
Advertising**

Contains Nonbinding Recommendations

Draft — Not for Implementation

TABLE OF CONTENTS

I.	INTRODUCTION.....	1
II.	BACKGROUND	2
III.	RECOMMENDATIONS FOR PRESENTING QUANTITATIVE EFFICACY AND RISK INFORMATION IN DIRECT-TO-CONSUMER PROMOTIONAL LABELING AND ADVERTISEMENTS	3
A.	Probability Presentations	3
	<i>1. Absolute Frequencies and Percentages</i>	<i>3</i>
	<i>2. Relative Frequencies.....</i>	<i>4</i>
B.	Formatting Quantitative Efficacy or Risk Information	5
C.	Visual Aids.....	6
D.	Quantitative Efficacy or Risk Information from the Control Group	8
	REFERENCES.....	9

Contains Nonbinding Recommendations

Draft — Not for Implementation

1 **Presenting Quantitative Efficacy and Risk Information in Direct-to-**
2 **Consumer Promotional Labeling and Advertisements**
3 **Guidance for Industry¹**
4

5
6 This draft guidance, when finalized, will represent the current thinking of the Food and Drug
7 Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not
8 binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the
9 applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible
10 for this guidance as listed on the title page.
11

12
13
14
15 **I. INTRODUCTION**
16

17 This draft guidance provides recommendations for presenting quantitative efficacy and risk
18 information in direct-to-consumer (DTC) promotional labeling and advertisements for
19 prescription human drugs and biological products and prescription animal drugs and in DTC
20 promotional labeling for over-the-counter animal drugs² (collectively *promotional materials*).³
21 For the purposes of this guidance, quantitative efficacy and risk information refers to information
22 that numerically addresses the likelihood or magnitude of a drug's effectiveness or risks.
23

24 The guidance outlines FDA's recommendations for how firms⁴ that include quantitative efficacy
25 or risk information in DTC promotional materials for their drugs can make the language and
26 presentation more consumer-friendly.⁵ These recommendations apply to DTC promotional

¹ This guidance has been prepared by the Office of Prescription Drug Promotion in the Center for Drug Evaluation and Research, in consultation with the Center for Biologics Evaluation and Research and the Center for Veterinary Medicine at the Food and Drug Administration.

² The term *drugs* in this guidance refers to prescription human and animal drugs, prescription biologics, and over-the-counter animal drugs.

³ *Promotional labeling* is generally any labeling other than the FDA-required labeling. Examples of materials that may be considered promotional labeling, such as brochures, booklets, and mailing pieces, are described in 21 CFR 202.1(1)(2). The Federal Food, Drug, and Cosmetic Act (FD&C Act) does not define what constitutes an *advertisement*, but FDA regulations provide several examples, including "advertisements in published journals, magazines, other periodicals, and newspapers, and advertisements broadcast through media such as radio, television, and telephone communication systems" (21 CFR 202.1(1)(1)).

⁴ The term *firms* in this guidance refers to manufacturers, packers, and distributors of prescription drugs, as described in this guidance, and over-the-counter animal drugs, including their representatives.

⁵ This guidance is not intended to describe whether or when a presentation of quantitative efficacy or risk information would be truthful or non-misleading. FDA reminds firms that they are responsible for ensuring that their promotional materials are truthful and non-misleading and that they comply with applicable statutory and regulatory requirements. See, e.g., 21 U.S.C. 352(a), 352(n), and 321(n); 21 CFR 1.21; and 202.1(e)(5)(i) through (iii). Additionally, we note that there may be ways other than the recommendations provided in this draft guidance that would make presentations of quantitative efficacy or risk information consumer-friendly.

Contains Nonbinding Recommendations

Draft — Not for Implementation

27 materials regardless of the medium in which they are presented (e.g., print, electronic,
28 audiovisual, broadcast).

29
30 This guidance covers the following topics for presenting quantitative efficacy and risk
31 information in DTC promotional materials:

- 32
- 33 • Presenting probability information in terms of absolute frequencies, percentages, and
34 relative frequencies
 - 35 • Formatting quantitative efficacy or risk information
 - 36 • Using visual aids to illustrate quantitative efficacy or risk information
 - 37 • Providing quantitative efficacy or risk information for the treatment group and the control
38 group
- 39

40 In general, FDA’s guidance documents do not establish legally enforceable responsibilities.
41 Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only
42 as recommendations, unless specific regulatory or statutory requirements are cited. The use of
43 the word *should* in Agency guidances means that something is suggested or recommended, but
44 not required.

45
46

47 **II. BACKGROUND**

48
49 The Federal Food, Drug, and Cosmetic Act (FD&C Act) and its implementing regulations
50 generally require that promotional labeling and advertisements for drugs, including materials
51 directed toward consumers, be truthful and non-misleading, convey information about a drug’s
52 efficacy and its risks in a balanced manner, and reveal material facts about the drug.⁶ Firms
53 generally have flexibility with respect to the presentation of efficacy and risk information about
54 their products so long as the presentation is not false or misleading and complies with other
55 applicable statutory and regulatory requirements. When firms develop DTC promotional
56 materials, they should consider how to best convey information about a drug’s efficacy and risks
57 so the audience understands it. This includes consideration of whether to provide efficacy and
58 risk information by using words, numbers, or visual aids, or a combination of these elements.

59
60 In recent years, FDA has observed an increase in quantitative presentations of efficacy and risk
61 information in DTC promotional materials submitted to the Agency. Recent research on the
62 communication of treatment information suggests that consumers can recall and comprehend
63 efficacy and risk information when it is provided quantitatively (Buchter et al. 2014;
64 O’Donoghue et al. 2014b; Schwartz et al. 2007; Schwartz et al. 2009; Sullivan et al. 2015;
65 Trevena et al. 2013; West et al. 2013; Woloshin et al. 2004). When compared to qualitative
66 descriptions of efficacy and risk information, quantitative information can improve consumers’
67 accuracy in estimating the drug’s benefits and risks (Sullivan et al. 2015; West et al. 2013). This
68 is due in part to how consumers differ in their interpretations of qualitative descriptors (e.g.,
69 *rare, common, most*) and how the context in which qualitative terms are presented can affect
70 how consumers understand them (Buchter et al. 2014; Fagerlin et al. 2007; Lipkus 2007;

⁶ See, e.g., 21 U.S.C. 352(a), 352(n), and 321(n); 21 CFR 1.21; and 202.1(e)(5)(i) through (iii).

Contains Nonbinding Recommendations

Draft — Not for Implementation

71 Viisschers et al. 2009). Quantitative efficacy or risk information may offer more precision than
72 qualitative information, which consumers can use to form more accurate perceptions about the
73 drug (Lipkus 2007).

74
75 Firms should ensure that DTC promotional materials containing quantitative efficacy or risk
76 information are accurate and understandable. FDA understands that firms may experience
77 challenges when determining how to present this kind of quantitative information in DTC
78 promotional materials. For these reasons, FDA is issuing this guidance to provide
79 recommendations for presenting quantitative efficacy and risk information in DTC promotional
80 materials and to encourage firms to follow these recommendations when including such
81 information in their DTC promotional materials.

82
83 The examples in this guidance are intended to illustrate recommended approaches to presenting
84 quantitative efficacy and risk information in DTC promotional materials. Each example is meant
85 to address a specific concept described in the guidance; a given example may not illustrate every
86 recommendation outlined. The examples do not encompass every potential promotional scenario
87 or consideration and do not necessarily reflect an evaluation of a complete promotional piece,
88 including whether the piece complies with other applicable requirements. All recommendations
89 discussed in this guidance should be taken into consideration even if not expressly illustrated in
90 an example.

91
92
93 **III. RECOMMENDATIONS FOR PRESENTING QUANTITATIVE EFFICACY AND**
94 **RISK INFORMATION IN DIRECT-TO-CONSUMER PROMOTIONAL**
95 **LABELING AND ADVERTISEMENTS**

96
97 **A. Probability Presentations**
98

99 Firms should consider the following recommendations when presenting quantitative probability
100 information about their drug's efficacy and risks.

101
102 *1. Absolute Frequencies and Percentages*
103

104 Firms presenting quantitative efficacy or risk probabilities in DTC promotional materials should
105 convey the information in terms of absolute frequencies (e.g., 57 out of 100) or percentages
106 (57%). Research suggests that using these formats to express probabilities when communicating
107 health information can improve consumers' comprehension and ability to recall the information
108 (Lipkus 2007; Zipkin et al. 2014). Additionally, consumers receiving information about a drug's
109 efficacy and risk rates in terms of absolute frequencies or percentages can more easily process
110 and evaluate the information than when the same information is in a format that requires them to
111 perform a calculation to interpret the probabilities (Lipkus 2007; O'Donoghue et al. 2014b;
112 Sullivan et al. 2015).

113
114 Example 1: A firm is developing a magazine advertisement and includes a presentation
115 showing that in clinical trials, most patients experienced a response after

Contains Nonbinding Recommendations

Draft — Not for Implementation

116 12 weeks of treatment with Drug X. The firm wants to add numeric values to the
117 presentation to help consumers understand this information.

118
119 To communicate this information in a manner that will facilitate consumer
120 comprehension, the firm presents the information as an absolute frequency: *In a*
121 *clinical trial, 78 out of 100 patients experienced a response after 12 weeks of*
122 *treatment with Drug X.*

123
124 Example 2: A firm plans to include quantitative information in a patient mailer for Drug X
125 about the most common adverse reaction associated with Drug X: nausea.

126
127 To allow consumers to easily process this information, the firm presents the
128 information as a percentage: *In a clinical trial, 45% of patients experienced*
129 *nausea during 12 weeks of treatment with Drug X, compared to 18% of patients*
130 *during treatment with Drug Y.*

131
132 2. *Relative Frequencies*

133
134 Research suggests that consumers do not understand relative frequencies (e.g., 33% reduction in
135 symptoms; 3 times as likely to experience a side effect) in health communications as easily as
136 they understand other formats for presenting probabilities, such as absolute frequencies or
137 percentages (Covey 2007; Fagerlin et al. 2007; Zipkin et al. 2014). Consumers may also find the
138 efficacy or risk probability described as a relative frequency harder to comprehend and more
139 favorable as compared to the absolute frequency, which could lead to consumers' over- or
140 underestimating how well the drug works or the magnitude of the risk associated with the drug
141 (Ancker et al. 2006; Covey 2007; Zipkin et al. 2014).

142
143 If firms choose to present efficacy or risk probabilities as relative frequencies, they should add
144 context to the relative frequency presentation to improve consumers' ability to accurately
145 understand the efficacy or risk information. Specifically, firms should include the corresponding
146 absolute probability measures in presentations of relative frequency measures to provide the
147 information in a way that does not require further calculation about the effect being
148 communicated (Covey 2007; O'Donoghue et al. 2014b; Sullivan et al. 2015).

149
150 Example 3: A firm is developing a DTC television advertisement for Drug X, which is
151 indicated to reduce the risk of stroke. In a clinical trial, the following absolute
152 risk reductions were observed: 1% of patients treated with Drug X had a stroke,
153 compared to 2% of patients in the control group. This represents a 50% relative
154 reduction in risk of stroke.

155
156 To communicate this information in the DTC television advertisement in a
157 manner that will facilitate consumer comprehension, the firm presents the
158 absolute risk percentages in direct conjunction with the 50% relative risk
159 reduction information: *In a clinical trial, Drug X reduced the risk of stroke by*
160 *50% (1% of patients treated with Drug X had a stroke, compared to 2% of*
161 *patients in the control group).*

Contains Nonbinding Recommendations

Draft — Not for Implementation

162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203

B. Formatting Quantitative Efficacy or Risk Information

Firms that provide quantitative efficacy or risk information about their drugs in DTC promotional materials should incorporate the following formatting recommendations:

- Present the information in the same numerical format throughout a promotional labeling piece or advertisement (Lipkus 2007; Trevena et al. 2013). For example, firms providing two probabilities about two efficacy outcomes should provide both probabilities as absolute frequencies or both probabilities as percentages. Firms should also consistently characterize efficacy or risk information quantitatively throughout a promotional piece, rather than alternating between qualitative descriptors and quantitative information to describe similar information or concepts.
- Use frequencies with the same denominator when providing more than one absolute frequency and consider using denominators that are multiples of 10 (Fagerlin et al. 2007; Lipkus 2007; Trevena, et al. 2013; Visschers et al. 2009).
- Express probabilities using whole numbers to the extent that the probabilities in whole numbers accurately reflect the numerical value being described in the promotional piece (Lipkus 2007; Zipkin et al. 2014).⁷ Where a whole number would not be appropriate, firms should express the value as is (e.g., as a decimal) instead of rounding the value up or down to the nearest whole number. For example, firms should not round probabilities less than 1 to the nearest whole number. Similarly, firms should not round probabilities to the nearest whole number when comparing probabilities that are so close in value that the difference between the probabilities would be lost if the values were expressed as a whole number or numbers. Firms also should ensure that quantitative probability information about a particular risk does not minimize or deter from information about the severity of the risk. For example, firms should not disproportionately emphasize the low probability of a serious risk occurring as a way to detract from the seriousness of that risk.

Example 4: A firm is developing a consumer brochure for Drug X and is considering whether to describe quantitative information about moderate symptom relief in patients treated with Drug X and treated with placebo in terms of absolute frequencies (9 out of 10 and 3 out of 10, respectively) or as percentages (90% and 30%, respectively).

Although either probability measure would be appropriate to describe these outcomes, to help consumers process the information, the firm should provide the outcomes for both the treatment and placebo groups in the same format (i.e., both outcomes as absolute frequencies or both outcomes as percentages): *In patients*

⁷ For values greater than 1, to express a value to the nearest whole number, the following principles apply: For amounts falling exactly halfway between two whole numbers or higher (e.g., 2.5 to 2.99), round up (e.g., 3); for values less than halfway between two whole numbers (e.g., 2.01 to 2.49), round down (e.g., 2).

Contains Nonbinding Recommendations

Draft — Not for Implementation

204 *treated with Drug X, 9 out of 10 patients experienced moderate symptom relief,*
205 *compared to 3 out of 10 patients who received placebo. Alternatively: In*
206 *patients treated with Drug X, 90% of patients experienced moderate symptom*
207 *relief, compared to 30% of patients who received placebo.*
208

209 Example 5: In a clinical trial for Drug X, 54% of patients treated with Drug X experienced
210 moderate symptom relief and 19% of patients treated with Drug X experienced
211 complete symptom relief, compared to 28% of patients treated with placebo and
212 2% of patients treated with placebo, respectively. The firm is developing a
213 patient booklet for Drug X that contains the following information: In a clinical
214 trial, the majority of patients experienced moderate symptom relief after treatment
215 with Drug X, and 19% of patients experienced complete symptom relief. In
216 patients treated with placebo, less than half of patients experienced moderate
217 symptom relief and 2% of patients experienced complete symptom relief.
218

219 To present the information consistently, the firm should include the “*majority of*
220 *patients (54%)*” and “*less than half of patients (28%)*” in the proposed patient
221 booklet. Alternatively, the firm could consistently present only the quantitative
222 information throughout the piece (e.g., “*...54% of patients treated with Drug X*
223 *experienced moderate symptom relief...*,” “*...28% of patients treated with placebo*
224 *experienced moderate symptom relief...*”).
225

226 C. Visual Aids

227
228 When DTC promotional materials contain quantitative efficacy or risk information, visual aids
229 such as graphs, tables, and icon arrays can be used to illustrate the information and put the
230 numerical values in context. Visual representations of efficacy and risk in DTC promotional
231 materials improve consumer comprehension of numeric values by illustrating patterns,
232 summarizing the data, and reducing the amount of mental calculations the consumer must
233 perform to extract meaning from the quantitative information (Ancker et al. 2006; Fagerlin et al.
234 2007; Lipkus 2007). Moreover, visual aids can improve consumers’ ability to accurately
235 understand how well a drug works and support decision making (Fagerlin et al. 2007; Garcia-
236 Retamero and Cokely 2013; Sullivan et al. 2016; Zipkin et al. 2014).
237

238 Visual aids in DTC promotional materials help consumers comprehend quantitative efficacy and
239 risk information, but all visual aid designs are not equally effective in conveying all types of
240 information (Fagerlin et al. 2007; Sullivan et al. 2016). Therefore, we recommend that firms
241 select the visual aid design that best communicates the quantitative efficacy or risk information
242 being presented. When choosing a visual aid to express quantitative efficacy or risk information
243 about a drug, firms should carefully consider the communication’s purpose and objectives
244 (Ancker et al. 2006; Fagerlin et al. 2007). For example, a bar graph is an appropriate format for
245 visually depicting comparisons between probabilities, whereas a line graph is more useful for
246 illustrating trends or changes over time (Ancker et al. 2006; Fagerlin et al. 2007; Lipkus 2007).
247 Additionally, firms should consider the following general recommendations when designing
248 visual aids to illustrate quantitative efficacy or risk information in their DTC promotional
249 materials:

Contains Nonbinding Recommendations

Draft — Not for Implementation

250

251 • Explain the purpose of the visual aid clearly and accurately and define the elements
252 displayed (Garcia-Retamero and Cokely 2013; Lipkus 2007). For example, firms should
253 include a title, header, or caption (written or oral depending on the media) and identify
254 the visual aid's variables, scales, and axes (when applicable).

255

256 • Make visual displays of numeric information proportionate to the quantity being
257 described (Ancker et al. 2006; Lipkus 2007). For example, the height of a bar on a bar
258 graph should be proportionate to the quantity it represents.

259

260 • Include visual representations of both the numerator and denominator of ratios or
261 frequencies (Ancker et al. 2006). For example, an icon array should illustrate the number
262 of people who experienced the effect (numerator) out of the total number of people
263 studied (denominator).


264

265 Example 6: Infection is a risk associated with the use of Drug X. The firm responsible
266 for Drug X wants to include a visual aid on Drug X's consumer website to
267 communicate information from Drug X's approved labeling about the number of
268 patients who did not experience an infection, those who experienced a mild to
269 moderate infection, and those who experienced a severe or life-threatening
270 infection after treatment with Drug X compared to patients treated with placebo.

271

272 *The firm prepares a bar graph to present this information because it best*
273 *facilitates the comprehension of visual comparisons between probabilities. As*
274 *illustrated below, the firm includes a title that describes what the bar graph*
275 *portrays, labels the scales and variables, and ensures that the values graphically*
276 *displayed are proportionate to the quantities being described.*

277



278

279

D. Quantitative Efficacy or Risk Information from the Control Group

281

282 Firms that provide quantitative efficacy or risk information about a drug in DTC promotional
283 materials should provide quantitative information from both the treatment group and the relevant
284 control group. Information from the control group plays an important role in evaluating a drug's

Contains Nonbinding Recommendations

Draft — Not for Implementation

285 benefits and risks (O'Donoghue et al. 2014a). Including efficacy or risk measures observed in
286 the control group quantitatively when providing corresponding quantitative measures observed in
287 the treatment group improves consumers' ability to process and comprehend the drug's efficacy
288 and risks and can lead to more-informed decision making (O'Donoghue et al. 2014a; Schwartz et
289 al. 2009). Research suggests that consumers can use the information about the control group to
290 form accurate perceptions about a drug's efficacy and risk (O'Donoghue et al. 2014a; Schwartz
291 et al. 2009; Sullivan et al. 2013). When including control group information in promotional
292 materials, firms should also ensure that they accurately describe the comparator used in the
293 control group.

294

295 Example 7: In a clinical trial of 173 participants, 68% of patients who were treated with Drug
296 X plus a sulfonylurea experienced a reduction in blood glucose levels, while 33%
297 of patients treated with a sulfonylurea alone experienced a reduction in blood
298 glucose levels. The firm is developing a social media web page for Drug X and
299 includes a presentation that 68% of patients treated with Drug X plus a
300 sulfonylurea experienced a reduction in blood glucose levels.

301

302 *The firm should also include that 33% of patients treated with a sulfonylurea*
303 *alone experienced a reduction in blood glucose levels.*

304

Contains Nonbinding Recommendations

Draft — Not for Implementation

REFERENCES

- 305
306
307 Ancker, JS, Y Senathirajah, R Kukafka, and JB Starren, 2006, *Design Features of Graphs in*
308 *Health Risk Communication: A Systematic Review*, J Am Med Inform Assoc, 13(6):608–618.
309
310 Buchter, RB, D Fechtelpeter, M Knelangen, M Ehrlich, and A Waltering, 2014, *Words or*
311 *numbers? Communicating Risk of Adverse Effects in Written Consumer Health Information: A*
312 *Systematic Review and Meta-Analysis*, BMC Med Inform Decis Mak, 14:76.
313
314 Covey J, 2007, *A Meta-Analysis of the Effects of Presenting Treatment Benefits in Different*
315 *Formats*, Med Decis Making, 27(5):638–654.
316
317 Fagerlin, A, PA Ubel, DM Smith, and BJ Zikmund-Fisher, 2007, *Making Numbers Matter:*
318 *Present and Future Research in Risk Communication*, Am J Health Behav, 31(Suppl 1):S47–56.
319
320 Garcia-Retamero, R and ET Cokely, 2013, *Communicating Health Risks with Visual Aids*, Curr
321 *Dir Psychol Sci*, 22(5):392–399.
322
323 Lipkus, IM, 2007, *Numeric, Verbal, and Visual Formats of Conveying Health Risks: Suggested*
324 *Best Practices and Future Recommendations*, Med Decis Making, 27(5):696–713.
325
326 O’Donoghue, AC, HW Sullivan, and KJ Aikin, 2014a, *Randomized Study of Placebo and*
327 *Framing Information in Direct-to-Consumer Print Advertisements for Prescription Drugs*, Ann
328 *Behav Med*, 48(3):311–322.
329
330 O’Donoghue, AC, HW Sullivan, KJ Aikin, D Chowdhury, RR Moultrie, and DJ Rupert, 2014b,
331 *Presenting Efficacy Information in Direct-to-Consumer Prescription Drug Advertisements*,
332 *Patient Educ Couns*, 95(2):271–280.
333
334 Schwartz, LM, S Woloshin, and HG Welch, 2007, *The Drug Facts Box: Providing Consumers*
335 *with Simple Tabular Data on Drug Benefit and Harm*, Medical Decision Making, 27:655–662.
336
337 Schwartz, LM, S Woloshin, and HG Welch, 2009, *Using a Drug Facts Box to Communicate*
338 *Drug Benefits and Harms: Two Randomized Trials*, Ann Intern Med, 150(8):516–527.
339
340 Sullivan, HW, AC O’Donoghue, and KJ Aikin, 2013, *Presenting Quantitative Information About*
341 *Placebo Rates to Patients*, JAMA Intern Med, 173(21):2006–2007.
342
343 Sullivan, HW, AC O’Donoghue, and KJ Aikin, 2015, *Communicating Benefit and Risk*
344 *Information in Direct-to-Consumer Print Advertisements: A Randomized Study*, Ther Innov
345 *Regul Sci*, 49(4):493–502.
346
347 Sullivan, HW, AC O’Donoghue, KJ Aikin, D Chowdhury, RR Moultrie, and DJ Rupert, 2016,
348 *Visual Presentations of Efficacy Data in Direct-to-Consumer Prescription Drug Print and*
349 *Television Advertisements: A Randomized Study*, Patient Educ Couns, 99:790–799.
350

Contains Nonbinding Recommendations

Draft — Not for Implementation

- 351 Trevena, LJ, BJ Zikmund-Fisher, A Edwards, W Gaissmaier, M Galesic, PKJ Han, J King, ML
352 Lawson, SK Linder, I Lipkus, E Ozanne, E Peters, D Timmermans, and S Woloshin, 2013,
353 *Presenting Quantitative Information About Decision Outcomes: A Risk Communication Primer*
354 *for Patient Decision Aid Developers*, BMC Med Inform Decis Mak, 13(Supple 2):S7.
355
- 356 Visschers, VH, RM Meertens, WW Passchier, NN De Vries, 2009, *Probability Information in*
357 *Risk Communication: A Review of the Research Literature*, Risk Anal, 29(2):267–287.
358
- 359 West, SL, LB Squiers, L McCormack, BG Southwell, ES Brouwer, M Ashok, L Lux, V
360 Boudewyns, A O'Donoghue, and HW Sullivan, 2013, *Communicating Quantitative Risks and*
361 *Benefits in Promotional Prescription Drug Labeling or Print Advertising*, Pharmacoepidemiol
362 Drug Saf, 22(5):447–458.
363
- 364 Woloshin, S, LM Schwartz, and HG Welch, 2004, *The Value of Benefit Data in Direct-to-*
365 *Consumer Drug Ads*, Health Aff, Suppl Web Exclusives, W4:234–245.
366
- 367 Zipkin, DA, CA Umscheid, NL Keating, E Allen, K Aung, R Beyth, S Kaatz, DM Mann, JB
368 Sussman, D Korenstein, C Schardt, A Nagi, R Sloane, and DA Feldstein, 2014, *Evidence-Based*
369 *Risk Communication: A Systematic Review*, Ann Intern Med, 161(4):270–280.